{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:37:10Z","timestamp":1793979430487,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite recent advances in chemotherapy for gastrointestinal cancer, a crucial factor related to poor prognosis is reduced tolerance to chemotherapy induced by cancer cachexia. Fish oil (FO)-derived eicosapentaenoic acid (EPA) modulates inflammation in patients with various malignancies; however, the impact of FO-enriched nutrition as a combined modality therapy on clinical outcomes remains controversial. We systemically analysed chronological changes in biochemical and physiological status using bioelectrical impedance analysis in 128 gastrointestinal cancer patients provided with or without FO-enriched nutrition during chemotherapy. Furthermore, we evaluated the clinical significance of FO-enriched nutrition and clarified appropriate patient groups that receive prognostic benefits from FO-enriched nutrition during treatment of gastrointestinal cancer. The control group showed significant up-regulation of serum CRP) levels and no significant difference in both skeletal muscle mass and lean body mass. In contrast, the FO-enriched nutrition group showed no changes in serum CRP concentration and significantly increased skeletal muscle mass and lean body mass over time. Furthermore, high CRP levels significantly correlated with reduced tolerance to chemotherapy, and FO-enriched nutrition improved chemotherapy tolerance and prognosis, particularly in gastrointestinal cancer patients with a modified Glasgow prognostic score (mGPS) of 1 or 2. We conclude that FO-enriched nutrition may improve the prognosis of patients with cancer cachexia and systemic inflammation (i.e., those with a mGPS of 1 or 2).<\/jats:p>","DOI":"10.1038\/s41598-017-05278-0","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T14:03:48Z","timestamp":1498831428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia"],"prefix":"10.1038","volume":"7","author":[{"given":"Yumiko","family":"Shirai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinaga","family":"Okugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahi","family":"Hishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Shintani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yokoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Urata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Toiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyoshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Mohri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Kusunoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4260-5334","authenticated-orcid":false,"given":"Donald C.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikao","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"key":"5278_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J Clin \n                           63, 11\u201330, doi:10.3322\/caac.21166 (2013).","journal-title":"CA Cancer J Clin"},{"key":"5278_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J Clin \n                           65, 87\u2013108, doi:10.3322\/caac.21262 (2015).","journal-title":"CA Cancer J Clin"},{"key":"5278_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol \n                           12, 489\u2013495, doi:10.1016\/S1470-2045(10)70218-7 (2011).","journal-title":"Lancet Oncol"},{"key":"5278_CR4","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2147\/TCRM.S79374","volume":"11","author":"M Suno","year":"2015","unstructured":"Suno, M. et al. Refractory cachexia is associated with increased plasma concentrations of fentanyl in cancer patients. Therapeutics and clinical risk management \n                           11, 751\u2013757, doi:10.2147\/tcrm.s79374 (2015).","journal-title":"Therapeutics and clinical risk management"},{"key":"5278_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.currproblcancer.2011.01.001","volume":"35","author":"NP Gullett","year":"2011","unstructured":"Gullett, N. P., Mazurak, V. C., Hebbar, G. & Ziegler, T. R. Nutritional interventions for cancer-induced cachexia. Curr Probl Cancer \n                           35, 58\u201390, doi:10.1016\/j.currproblcancer.2011.01.001 (2011).","journal-title":"Curr Probl Cancer"},{"key":"5278_CR6","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","volume":"15","author":"CM Prado","year":"2009","unstructured":"Prado, C. M. et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res \n                           15, 2920\u20132926, doi:10.1158\/1078-0432.CCR-08-2242 (2009).","journal-title":"Clin Cancer Res"},{"key":"5278_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/01635581.2014.894103","volume":"66","author":"M Barret","year":"2014","unstructured":"Barret, M. et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer \n                           66, 583\u2013589, doi:10.1080\/01635581.2014.894103 (2014).","journal-title":"Nutr Cancer"},{"key":"5278_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00520-014-2418-6","volume":"23","author":"HW Jung","year":"2015","unstructured":"Jung, H. W. et al. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer \n                           23, 687\u2013694, doi:10.1007\/s00520-014-2418-6 (2015).","journal-title":"Support Care Cancer"},{"key":"5278_CR9","first-page":"5037","volume":"35","author":"M Shibutani","year":"2015","unstructured":"Shibutani, M. et al. Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer. Anticancer research \n                           35, 5037\u20135046 (2015).","journal-title":"Anticancer research"},{"key":"5278_CR10","doi-asserted-by":"publisher","first-page":"e3504","DOI":"10.1097\/MD.0000000000003504","volume":"95","author":"MC Hsieh","year":"2016","unstructured":"Hsieh, M. C. et al. A Prognostic Model Using Inflammation- and Nutrition-Based Scores in Patients With Metastatic Gastric Adenocarcinoma Treated With Chemotherapy. Medicine \n                           95, e3504, doi:10.1097\/md.0000000000003504 (2016).","journal-title":"Medicine"},{"key":"5278_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/1534735404264736","volume":"3","author":"DH Jho","year":"2004","unstructured":"Jho, D. H., Cole, S. M., Lee, E. M. & Espat, N. J. Role of omega-3 fatty acid supplementation in inflammation and malignancy. Integrative cancer therapies \n                           3, 98\u2013111, doi:10.1177\/1534735404264736 (2004).","journal-title":"Integrative cancer therapies"},{"key":"5278_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.plefa.2007.10.015","volume":"77","author":"PC Calder","year":"2007","unstructured":"Calder, P. C. Immunomodulation by omega-3 fatty acids. Prostaglandins, leukotrienes, and essential fatty acids \n                           77, 327\u2013335, doi:10.1016\/j.plefa.2007.10.015 (2007).","journal-title":"Prostaglandins, leukotrienes, and essential fatty acids"},{"key":"5278_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/tox.20546","volume":"26","author":"M Li","year":"2011","unstructured":"Li, M. et al. Protective effects of eicosapentaenoic acid on genotoxicity and oxidative stress of cyclophosphamide in mice. Environmental toxicology \n                           26, 217\u2013223, doi:10.1002\/tox.20546 (2011).","journal-title":"Environmental toxicology"},{"key":"5278_CR14","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.1158\/1078-0432.CCR-10-1990","volume":"16","author":"L Fini","year":"2010","unstructured":"Fini, L. et al. Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in Apc(Min\/+) mice. Clin Cancer Res \n                           16, 5703\u20135711, doi:10.1158\/1078-0432.ccr-10-1990 (2010).","journal-title":"Clin Cancer Res"},{"key":"5278_CR15","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1200\/JCO.2005.04.5724","volume":"24","author":"KC Fearon","year":"2006","unstructured":"Fearon, K. C. et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol \n                           24, 3401\u20133407, doi:10.1200\/JCO.2005.04.5724 (2006).","journal-title":"J Clin Oncol"},{"key":"5278_CR16","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1136\/gut.52.10.1479","volume":"52","author":"KC Fearon","year":"2003","unstructured":"Fearon, K. C. et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut \n                           52, 1479\u20131486 (2003).","journal-title":"Gut"},{"key":"5278_CR17","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/cncr.10324","volume":"94","author":"C Miki","year":"2002","unstructured":"Miki, C. et al. Intra-tumoral interleukin-6 down-regulation system and genetic mutations of tumor suppressor genes in colorectal carcinoma. Cancer \n                           94, 1584\u20131592 (2002).","journal-title":"Cancer"},{"key":"5278_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/sj.bjc.6605827","volume":"103","author":"Y Okugawa","year":"2010","unstructured":"Okugawa, Y. et al. Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer. British journal of cancer \n                           103, 787\u2013795, doi:10.1038\/sj.bjc.6605827 (2010).","journal-title":"British journal of cancer"},{"key":"5278_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00595-013-0622-5","volume":"44","author":"Y Mohri","year":"2014","unstructured":"Mohri, Y. et al. Correlation between preoperative systemic inflammation and postoperative infection in patients with gastrointestinal cancer: a multicenter study. Surgery today \n                           44, 859\u2013867, doi:10.1007\/s00595-013-0622-5 (2014).","journal-title":"Surgery today"},{"key":"5278_CR20","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3892\/ol.2013.1308","volume":"5","author":"Y Toiyama","year":"2013","unstructured":"Toiyama, Y. et al. Evaluation of preoperative C-reactive protein aids in predicting poor survival in patients with curative colorectal cancer with poor lymph node assessment. Oncology letters \n                           5, 1881\u20131888, doi:10.3892\/ol.2013.1308 (2013).","journal-title":"Oncology letters"},{"key":"5278_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.clnu.2012.05.009","volume":"32","author":"L Thoresen","year":"2013","unstructured":"Thoresen, L. et al. Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clinical nutrition (Edinburgh, Scotland) \n                           32, 65\u201372, doi:10.1016\/j.clnu.2012.05.009 (2013).","journal-title":"Clinical nutrition (Edinburgh, Scotland)"},{"key":"5278_CR22","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3945\/jn.110.123521","volume":"140","author":"RA Murphy","year":"2010","unstructured":"Murphy, R. A., Mourtzakis, M., Chu, Q. S., Reiman, T. & Mazurak, V. C. Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. The Journal of nutrition \n                           140, 1602\u20131606, doi:10.3945\/jn.110.123521 (2010).","journal-title":"The Journal of nutrition"},{"key":"5278_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s13539-014-0164-8","volume":"5","author":"S von Haehling","year":"2014","unstructured":"von Haehling, S. & Anker, S. D. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. Journal of cachexia, sarcopenia and muscle \n                           5, 261\u2013263, doi:10.1007\/s13539-014-0164-8 (2014).","journal-title":"Journal of cachexia, sarcopenia and muscle"},{"key":"5278_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.nut.2014.12.002","volume":"31","author":"G Pappalardo","year":"2015","unstructured":"Pappalardo, G., Almeida, A. & Ravasco, P. Eicosapentaenoic acid in cancer improves body composition and modulates metabolism. Nutrition (Burbank, Los Angeles County, Calif.) \n                           31, 549\u2013555, doi:10.1016\/j.nut.2014.12.002 (2015).","journal-title":"Nutrition (Burbank, Los Angeles County, Calif.)"},{"key":"5278_CR25","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/cncr.25709","volume":"117","author":"RA Murphy","year":"2011","unstructured":"Murphy, R. A. et al. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer \n                           117, 1775\u20131782, doi:10.1002\/cncr.25709 (2011).","journal-title":"Cancer"},{"key":"5278_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CM Prado","year":"2008","unstructured":"Prado, C. M. et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol \n                           9, 629\u2013635, doi:10.1016\/s1470-2045(08)70153-0 (2008).","journal-title":"Lancet Oncol"},{"key":"5278_CR27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ajcn\/83.6.1345","volume":"83","author":"KC Fearon","year":"2006","unstructured":"Fearon, K. C., Voss, A. C. & Hustead, D. S. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. The American journal of clinical nutrition \n                           83, 1345\u20131350 (2006).","journal-title":"The American journal of clinical nutrition"},{"key":"5278_CR28","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1200\/JCO.2015.61.4578","volume":"33","author":"HI Hurwitz","year":"2015","unstructured":"Hurwitz, H. I. et al. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. J Clin Oncol \n                           33, 4039\u20134047, doi:10.1200\/jco.2015.61.4578 (2015).","journal-title":"J Clin Oncol"},{"key":"5278_CR29","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1038\/bjc.2015.120","volume":"112","author":"T Kalsi","year":"2015","unstructured":"Kalsi, T. et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. British journal of cancer \n                           112, 1435\u20131444, doi:10.1038\/bjc.2015.120 (2015).","journal-title":"British journal of cancer"},{"key":"5278_CR30","unstructured":"Edge SB BD, C. C., Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer. (2010)."},{"key":"5278_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3892\/etm.2010.175","volume":"2","author":"Y Toiyama","year":"2011","unstructured":"Toiyama, Y. et al. Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med \n                           2, 95\u2013101, doi:10.3892\/etm.2010.175 (2011).","journal-title":"Exp Ther Med"},{"key":"5278_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1017\/S0029665108007131","volume":"67","author":"DC McMillan","year":"2008","unstructured":"McMillan, D. C. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. The Proceedings of the Nutrition Society \n                           67, 257\u2013262, doi:10.1017\/s0029665108007131 (2008).","journal-title":"The Proceedings of the Nutrition Society"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05278-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05278-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05278-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T06:20:09Z","timestamp":1671776409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05278-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["5278"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-05278-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,6]]},"assertion":[{"value":"2 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4826"}}